Lancet Haematol: Ibtinib Joint FCR for initial treatment of young CLL patients: a single arm, multicenter, Phase 2 clinical study
-
Last Update: 2020-06-24
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
FCR programs consisting of fluoradarabin, cyclophosatine and rituximatosis can improve PFS in CLL patients with iGHV mutations in young (-65 years of age) chemotherapy toleranceHowever, patients who do not have the IGHV mutation often do not get lasting resultsIbtinib's therapeutic response in CLL patients is not affected by the IGHV mutation state, but requires long-term use..This article is only available for readingMace Medical App, please scan the QR code and download the app directly
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
